$HIMS · Schwab Network · 2026-11-10
在意外亏损、营收与订阅用户数双双不及预期、指引低于市场共识之后,HIMS 下跌 13.5% 至约 19 美元,年初至今跌幅接近 40%。说话者预计其将在当前水平附近企稳,20 美元为主要支撑位,并卖出一份 12 月虚值看跌期权价差;他认为增长将持续但放缓,肽类业务的利好正在消退,两位数增长可能已经结束,但公司本身依然稳健。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
我们来看一下 Hims and Hers 的走势图。这家医疗健康公司本季度意外转为亏损,并收窄了全年销售展望,股价因此承压。
Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.
这是我们在一年走势图上看到的情况。它已经回落了相当多。Hims and Hers 目前下跌约13.5%,股价在19美元出头。所以这是今天早盘交易的焦点。
So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.
那个意外亏损、下调指引,还有销售疲软,对它来说是一个致命的组合。现在我们看到它下跌13.5%,延续了 Hims and Hers 在盘后交易中的跌势。
I mean, that surprise loss, the guidance cut here, uh light sales, it was a lethal combination for him. Now we're down 13.5% continuing the drop off that we saw in after hours trade for him and hers.
这里有很多问题。营收不及预期,订阅数不及预期,盈利也不及预期,出现了意外亏损。他们报告每股亏损14美分,而市场预期是每股盈利6美分。所以一开局就很糟糕。
Uh there were a lot of issues here. They missed on revenue. They missed on subscriptions. They missed on earnings with that surprise loss. They reported a loss of 14 cents a share.
Expectations were for earnings of 6 cents a share. So that started things off on a bad note.
然后是营收8.904亿美元,同比增长49%,但比分析师预期低了约300万美元。所以不算大幅不及预期,但仍然是不及预期。
Then we got revenue of $890.4 million. It was a gain of 49% year-over-year, but it did miss analyst expectations by about $3 million. So, not a huge miss, but still a miss.
他们报告本季度净亏损3300万美元,而去年同期为净利润1580万美元。市场一致预期是正的1390万美元。所以出现了相当明显的不及预期,这些意外亏损就在这里体现出来。
They reported a net loss of $33 million for the quarter compared with a net income of 15.8 million a year ago. Consensus was looking for it to be positive $13.9 million. So, some pretty significant misses with those surprise losses coming up here.
订阅用户数增长13%,达到约279万。每平均用户营收也增长约30%,达到105美元。但华尔街的预期仍然更高。这一项也不及预期。
Subscriber count was up 13% to about 2.79 million subscribers. Revenue per average subscriber also increased about 30% to $105. But again, Wall Street expected better here. That was a miss as well.
不过,他们第三季度营收49%的增长,已经是连续第二个季度加速。国内营收同比增长21%,国际营收增长321%。而对于当前第四季度,HIMS 预计营收约为8.75亿至8.95亿美元。
他们预计 Ibidon 数字为7000万至9000万美元,反映出8%至10%的 IBAon 利润率。所有这些都低于华尔街的预期。几乎全面不及预期。
That 49% growth in the third quarter in terms of uh their revenue though was their second straight quarter of acceleration. Domestic revenue is up 21% from a year ago. International revenue increased 321%.
Um and for the current fourth quarter, HIMS expects revenue to be about 875 million to 895 million. They're projecting their Ibidon number of 70 to 90 million reflecting an IBAon margin of 8 to 10%.
All of those were underneath what the street was looking for. They were all misses pretty much across the board.
他们还收窄了全年指引,降至31.3亿至31.5亿美元,低于此前31亿至33亿美元的区间。Ibida 也被下调并收窄至2.57亿至2.77亿美元,反映出8%至9%的 Ibida 利润率。
所以,即使看全年数字,相比季度数字也可能意味着一些收缩。
They also narrowed their fullear guidance as well to a range of 3.13 billion to 3.15 down from a prior range of 3.1 to 3.3. Ibida also got dropped and narrowed 257 to 277 million reflecting an Ibida margin of 8 to 9%.
So that may mark some contraction even on the full year over the quarterly numbers.
所以,当我们看这个,Sam,这些走势完全抹去了他们上周宣布与 Eli Liy 达成协议、在其平台上销售其热门产品 Zepbound 和 foundo 之后所看到的涨幅。对他们来说,局面很艰难。
So I mean as we look at this Sam I mean these moves completely wiped out the gains that they saw last week after announcing this agreement with Eli Liy to sell its popular Zepbound and foundo on their platform. Uh just a tough setup for them.
他们正在大举投资人工智能和技术,试图推动业务的长期发展,但目前股价迅速下跌超过13.5%,这使得他们今年迄今下跌近40%。
They are investing heavily in AI and technology to try to drive the business long term, but right now seeing a swift move to the downside of more than 13 and a half percent, which puts them down almost 40% year to date.
是的,正如我们提到的,你和我今年一直在跟踪这只股票。那个热门的肽夏天并没有真正实现。我认为华尔街很多人多少是指望它的,但我们还得看监管路径如何发展。不过 Marley,谢谢你提供的细节。它现在正遭到惩罚。
Yeah, and as we mentioned, and you and I have been covering this stock for this year. I mean, that hot peptide summer didn't really materialize. I think a lot of the people on the street were kind of banking on that, but we'll have to see how that regulatory path goes.
But Marley, thanks for the details. It is getting punished right now.
是的,绝对。Sam,正如你提到的,这只股票基本上已经被狠狠修理了一顿,今天在财报发布后更是如此,财报表面上肯定不算好,但也不算真的很糟。营收仍在增长,对吧?尽管可能略低于分析师预期。
Yeah, absolutely. And uh Sam, and this is a stock that, as you alluded to, is basically been, you know, just taken out to the woodshed, even more so today post earnings that were uh certainly on the surface not great, but not really terrible.
Revenue still growing, right? although be maybe a little bit below the analyst expectations.
所以我预计这只股票会在这个位置附近企稳。图表上20美元看起来确实是过去几个季度的主要支撑位。所以我把希望寄托在那里,一直到12月。卖出略微虚值的看跌价差。之前大约是虚值10%。
卖出 D 2017 看跌价差,现在能收入超过1美元。所以我喜欢这个风险回报,风险也是有限的,如果需要进一步对冲,我还可以卖出更短期的看涨价差。
So I look for the stock to just settle in around here. Certainly $20 on the chart looks like major support going back several quarters. So I'm hanging my hat there going out to December.
Selling a slightly out of money put spread. Now earlier it was about 10% out of the money. Selling the D 2017 put spread bringing in over a buck right now. So like that return on risk, have defined risk as well, and I can sell shorter term call spreads if I need to hedge it further.
所以我认为 Hims 肯定是一家会继续增长的公司,尽管不是那种快速的速度。你提到了肽类产品,我们在那里没有看到回升。我认为未来他们大多数产品也不会再看到巨大的收益,但它仍然会是一家稳健的公司。
我认为两位数增长的那种增长期可能已经过去了,但至少未来仍会有稳健的增长。
So I think him certainly uh is a company that's going to continue to grow, albeit not at that rapid pace. You mentioned the peptides. We're not seeing the pickup there. And I think we'll stop seeing uh you know the huge benefits going forward on most of their products, but it'll still be a solid company.
I think the growth days uh of having uh doubledigit growth may be behind him but solid growth going forward at least for the future.
这个频道对 $HIMS 的历次判断
Schwab Network 在这只股票上共 3 条判断,这里只列相邻的几条。